Soleno Therapeutics (SLNO) reported preliminary Q4 net revenue Monday of $90 million to $92 million.
Analysts surveyed by FactSet expect $83.3 million.
The biotech company also said it has achieved profitability and positive cash flow and reported preliminary cash, cash equivalents and marketable securities of $500 million as of Dec. 31.
Shares of the company were up more than 3% in recent Monday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments